6547 Stock Overview
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Medigen Vaccine Biologics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$51.30 |
| 52 Week High | NT$81.50 |
| 52 Week Low | NT$48.20 |
| Beta | 0.80 |
| 1 Month Change | -3.75% |
| 3 Month Change | -18.70% |
| 1 Year Change | -25.11% |
| 3 Year Change | -70.63% |
| 5 Year Change | 117.34% |
| Change since IPO | 141.49% |
Recent News & Updates
Shareholder Returns
| 6547 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.5% | -4.1% | -2.6% |
| 1Y | -25.1% | -26.4% | 25.9% |
Return vs Industry: 6547 exceeded the TW Biotechs industry which returned -26.4% over the past year.
Return vs Market: 6547 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6547 volatility | |
|---|---|
| 6547 Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 4.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.4% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6547's share price has been volatile over the past 3 months.
Volatility Over Time: 6547's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | n/a | www.medigenvac.com |
Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan.
Medigen Vaccine Biologics Corporation Fundamentals Summary
| 6547 fundamental statistics | |
|---|---|
| Market cap | NT$16.86b |
| Earnings (TTM) | -NT$1.16b |
| Revenue (TTM) | NT$389.62m |
43.3x
P/S Ratio-14.5x
P/E RatioIs 6547 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6547 income statement (TTM) | |
|---|---|
| Revenue | NT$389.62m |
| Cost of Revenue | NT$159.40m |
| Gross Profit | NT$230.22m |
| Other Expenses | NT$1.39b |
| Earnings | -NT$1.16b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.53 |
| Gross Margin | 59.09% |
| Net Profit Margin | -297.68% |
| Debt/Equity Ratio | 44.4% |
How did 6547 perform over the long term?
See historical performance and comparison